GUFICBIOPharmaceuticals
Gufic Biosciences Ltd — Profit & Loss Statement
₹273.80
-4.82%
Gufic Biosciences Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 76450.46 | 0.02 Cr | — |
| Tax Rate For Calcs | 0.26 | 0.26 | 0.25 | 0.24 | — |
| Normalized EBITDA | 138.32 Cr | 148.05 Cr | 135.61 Cr | 149.71 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | 0.03 Cr | 0.07 Cr | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | 0.03 Cr | 0.07 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 69.65 Cr | 86.14 Cr | 79.70 Cr | 95.84 Cr | — |
| Reconciled Depreciation | 21.06 Cr | 17.02 Cr | 22.28 Cr | 18.93 Cr | — |
| Reconciled Cost Of Revenue | 374.70 Cr | 389.90 Cr | 340.90 Cr | 422.82 Cr | — |
| EBITDA | 138.32 Cr | 148.05 Cr | 135.64 Cr | 149.77 Cr | — |
| EBIT | 117.25 Cr | 131.03 Cr | 113.36 Cr | 130.84 Cr | — |
| Net Interest Income | -23.11 Cr | -15.36 Cr | -6.81 Cr | -3.49 Cr | — |
| Interest Expense | 23.11 Cr | 15.36 Cr | 6.64 Cr | 4.01 Cr | — |
| Normalized Income | 69.65 Cr | 86.14 Cr | 79.68 Cr | 95.79 Cr | — |
| Net Income From Continuing And Discontinued Operation | 69.65 Cr | 86.14 Cr | 79.70 Cr | 95.84 Cr | — |
| Total Expenses | 706.18 Cr | 677.81 Cr | 564.42 Cr | 583.92 Cr | — |
| Diluted Average Shares | 10.02 Cr | 9.86 Cr | 9.69 Cr | 9.69 Cr | 9.69 Cr |
| Basic Average Shares | 10.02 Cr | 9.86 Cr | 9.69 Cr | 9.69 Cr | 9.69 Cr |
| Diluted EPS | 6.95 | 8.74 | 8.22 | 9.89 | 4.56 |
| Basic EPS | 6.95 | 8.74 | 8.22 | 9.89 | 4.56 |
| Diluted NI Availto Com Stockholders | 69.65 Cr | 86.14 Cr | 79.70 Cr | 95.84 Cr | — |
| Net Income Common Stockholders | 69.65 Cr | 86.14 Cr | 79.70 Cr | 95.84 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 69.65 Cr | 86.14 Cr | 79.70 Cr | 95.84 Cr | — |
| Minority Interests | 8000.00 | 0.00 | — | — | — |
| Net Income Including Noncontrolling Interests | 69.65 Cr | 86.14 Cr | 79.70 Cr | 95.84 Cr | — |
| Net Income Continuous Operations | 69.65 Cr | 86.14 Cr | 79.70 Cr | 95.84 Cr | — |
| Tax Provision | 24.49 Cr | 29.54 Cr | 27.02 Cr | 31.00 Cr | — |
| Pretax Income | 94.14 Cr | 115.67 Cr | 106.72 Cr | 126.84 Cr | — |
| Other Non Operating Income Expenses | 3.63 Cr | 2.18 Cr | 1.13 Cr | 0.46 Cr | — |
| Special Income Charges | 0.00 | 0.00 | 0.03 Cr | 0.07 Cr | — |
| Net Non Operating Interest Income Expense | -23.11 Cr | -15.36 Cr | -6.81 Cr | -3.49 Cr | — |
| Interest Expense Non Operating | 23.11 Cr | 15.36 Cr | 6.64 Cr | 4.01 Cr | — |
| Operating Income | 113.63 Cr | 128.85 Cr | 115.33 Cr | 129.10 Cr | — |
| Operating Expense | 331.48 Cr | 287.92 Cr | 223.52 Cr | 161.11 Cr | — |
| Other Operating Expenses | 183.36 Cr | 161.27 Cr | 89.87 Cr | 88.24 Cr | — |
| Depreciation And Amortization In Income Statement | 21.06 Cr | 17.02 Cr | 22.28 Cr | 18.93 Cr | — |
| Depreciation Income Statement | 21.06 Cr | 17.02 Cr | 22.28 Cr | 18.93 Cr | — |
| Gross Profit | 445.10 Cr | 416.77 Cr | 338.85 Cr | 290.21 Cr | — |
| Cost Of Revenue | 374.70 Cr | 389.90 Cr | 340.90 Cr | 422.82 Cr | — |
| Total Revenue | 819.81 Cr | 806.67 Cr | 679.75 Cr | 713.02 Cr | — |
| Operating Revenue | 819.81 Cr | 806.67 Cr | 679.75 Cr | 713.02 Cr | — |
| Interest Income | — | 1.41 Cr | 1.41 Cr | 1.88 Cr | 1.45 Cr |
| Rent Expense Supplemental | — | 1.47 Cr | 1.34 Cr | 2.39 Cr | 1.04 Cr |
| Other Special Charges | — | 2.30 Cr | -0.03 Cr | -0.07 Cr | -0.04 Cr |
| Total Other Finance Cost | — | 0.80 Cr | 1.59 Cr | 1.36 Cr | 1.87 Cr |
| Interest Income Non Operating | — | 1.41 Cr | 1.41 Cr | 1.88 Cr | 1.45 Cr |
| Research And Development | — | 5.41 Cr | 5.16 Cr | 4.43 Cr | 2.10 Cr |
| Selling General And Administration | — | 20.71 Cr | 20.86 Cr | 19.77 Cr | 11.06 Cr |
| Selling And Marketing Expense | — | 2.12 Cr | 5.96 Cr | 3.34 Cr | 1.86 Cr |
| General And Administrative Expense | — | 18.59 Cr | 14.90 Cr | 16.43 Cr | 9.20 Cr |
| Rent And Landing Fees | — | 1.47 Cr | 1.34 Cr | 2.39 Cr | 1.04 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Gufic Biosciences Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.